LLY
Eli Lilly and Company
LLY has the edge over UTHR overall, supported by stronger modeled upside and stronger valuation.
UTHR
United Therapeutics Corporation
UTHR trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
UTHR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
UTHR's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
UTHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $321 | -46% |
| Fair | 16x | $423 | -29% |
| Expensive | 19x | $511 | -14% |
| Current | 22x | $593 | — |
| Forward | 25x | $593 | — |
Historical ranges are pointers, not guarantees.
UTHR has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over UTHR on the outlook, with more favorable valuation and earnings expectations.
UTHR Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect UTHR's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over UTHR on earnings, with stronger typical year-over-year growth.
UTHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.18 | -8.6% |
| Q3 2026 | $26.46 | +0.1% |
| Q2 2026 | $27.91 | +8.8% |
| Q1 2026 | $27.05 | +7.8% |
| Q4 2025 | $27.86 | +13% |
| Q3 2025 | $26.43 | +16% |
| Q2 2025 | $25.66 | +18% |
| Q1 2025 | $25.10 | +19% |
| Q4 2024 | $24.64 | +24% |
UTHR's earnings per share have climbed steadily: $26.46 over the past year, about the same as the year before, and higher year over year for 19 quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over UTHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
UTHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $832.5M | +4.1% |
| Q2 2026 | $783.3M | -1.9% |
| Q1 2026 | $781.5M | -1.6% |
| Q4 2025 | $790.2M | +7.4% |
| Q3 2025 | $799.5M | +6.8% |
| Q2 2025 | $798.6M | +12% |
| Q1 2025 | $794.4M | +17% |
| Q4 2024 | $735.9M | +20% |
UTHR's revenue has held roughly level: $833M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | -12 points |
| Q2 2026 | 42% | -3.4 points |
| Q1 2026 | 42% | -6.5 points |
| Q4 2025 | 45% | -3.5 points |
| Q3 2025 | 49% | +2.8 points |
| Q2 2025 | 46% | +0.9 points |
| Q1 2025 | 48% | -4.4 points |
| Q4 2024 | 49% | +6.3 points |
UTHR has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over UTHR on cash flow, with more consistent year-over-year improvement.
UTHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $125.8M | -64% |
| Q2 2026 | $205.6M | +59% |
| Q1 2026 | $362.5M | -6.2% |
| Q4 2025 | $173.3M | -32% |
| Q3 2025 | $351.6M | +17% |
| Q2 2025 | $129.5M | -31% |
| Q1 2025 | $386.3M | +14% |
| Q4 2024 | $254.5M | +253% |
UTHR's free cash flow has been positive every quarter for seven years: $867M over the past year, down 23% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
UTHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -500K shares |
| 1 year | -4.2% | -2M shares |
| 3 years | -8.9% | -4.4M shares |
| 5 years | -4.8% | -2.3M shares |
| Available history | +3.4% | +1.5M shares |
UTHR has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | — |
| Q1 2026 | $1.5B |
| Q4 2025 | — |
| Q3 2025 | $1B |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
UTHR spent $2B buying back its own shares over the past year, up 100% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
UTHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.2x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -1.0x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
UTHR has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
UTHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.5 | Neutral |
| Stochastic | 80.5 | Overbought |
UTHR's weekly RSI is 61 (neutral) and its Stochastic is 81 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
UTHR PE vs Healthcare Sector
| Metric | UTHR | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 13% below |
| PE % | 100 | 29 | 71 pts above |
UTHR has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
UTHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $555.1 | 6.9% above |
| 20 week MA | $533.6 | 11% above |
| 50 week MA | $527.2 | 13% above |
| 100 week MA | $438.2 | 35% above |
| 200 week MA | $351.1 | 69% above |
UTHR is in an uptrend: it's above all five of its weekly moving averages, and 69% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over UTHR on returns for 2026, with the stronger performance.
UTHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.8 | $149.8 | +69% |
| 2021 | $149.8 | $214.0 | +43% |
| 2022 | $214.0 | $278.8 | +30% |
| 2023 | $278.8 | $219.9 | -21% |
| 2024 | $219.9 | $360.0 | +64% |
| 2025 | $360.0 | $507.2 | +41% |
| 2026 YTD | $507.2 | $593.3 | +17% |
UTHR has finished higher in five of the last six years, two of them by more than 50%. It's up 17% so far in 2026.